Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

“…A USA study [ 15 ] evaluating 1,956 patients according to the antiplatelet therapy prior to and during admission found lower in-hospital mortality in the group with ASA during admission after applying PSM (HR = 0.52, 95% CI 0.34–0.81). A recent meta-analysis [ 16 ] reported that ASA intake (prior or initiated during hospitalization) was independently associated with lower mortality in patients with COVID-19. When analyzing the results of the study, it is important to take into account the possible favorable effects of other important cardiovascular drug classes, especially renin–angiotensin–aldosterone system inhibitors and statins [ 17 , 18 ].…”

Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis

“…Many studies did not adequately report medications used by the patients, as shown in meta-regression analysis, medications may significantly affect the benefit of DPP-IV inhibitor in patients with COVID-19. There are other medications that were not adequately reported by most of the studies that may affect prognosis in patients with diabetes and COVID-19 [ 76 , 77 ].…”

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

“…The dose and length of ivermectin administration varied across the studies. Most of the studies also did not report important parameters such as chronic kidney disease, heart disease, medications for chronic diseases [ 46 ], and laboratory parameters such as d-dimer and c-reactive proteins which may affect prognosis. Thus adequately powered double-blinded placebo-controlled RCTs with similar baseline characteristics and dosing among the intervention and control groups are required before a definite conclusion can be made.…”